Speakers

  • Recommend
  • Tweet
  • Print
  • Email

Below is a list of the speaker who will be at the 2014 BIO Latin America conference. To view the full program schedule, please click here.

 

Photo Name and Title Panel, Date, Time, Location
Joseph P. Allen
Allen and Associates
President

Joe Allen served on the U.S. Senate Judiciary Committee for Senator Birch Bayh (D-IN) securing passage of the Bayh-Dole Act which fostered R&D partnerships between research universities and U.S. industry.  The Economist Technology Quarterly called this law “possibly the most inspired piece of legislation to be enacted in America over the past half century.” At the U.S. Department of Commerce, Joe served as the Director of the Office of Technology Commercialization.   He was instrumental in the passage of major laws allowing U.S. industry to perform joint R&D with federal laboratories. Allen’s office oversaw Executive branch implementation of technology transfer laws and related presidential policy directives. He served as the President of the National Technology Transfer Center, established by Congress to promote industry/private sector R&D cooperation. In 2008 he founded Allen and Associates a consulting firm specializing in technology management issues. Joe was the lead witness before the South Africa parliament on their version of Bayh-Dole that was enacted into law.  In 2013, Joe co-chaired the White House Lab to Market Summit. The Association of University Technology Managers presented Joe with the Driving Innovation Award “For His Tireless Work and Support as a Champion for the Bayh-Dole Act during the Past 30 Years.” 
 

Tech Transfer: Industry and University Collaborations
Wednesday, September 10, 2014
16:30 - 16:55
Vidigal A, B, & C
Reginaldo Arcuri
Grupo Farma Brasil
President

Reginaldo Braga Arcuri has been Chief Executive Officer of the Grupo FarmaBrasil, Association formed by brazilian pharmaceutical companies: Ache, Biolab, Bionovis, Cristália, EMS, Eurofarma, Hypermarcas, Hebron, Libbs, Orygen and União Química, all focusing on research and development, generics and innovative drugs, from 2011 on. President of the Brazilian Agency for Industrial Development (ABDI), and of the BNDES Audit Committee from 2007 to 2010. National Secretary for Production Development (2000-2002). Director of the Secretariat of MERCOSUL (2003 – 2005). Secretary of State for Industry and Commerce of Minas Gerais (1995 – 1996). President of the Institute of Integrated Development of Minas Gerais (2006 – 2007). Professor of the History Department of the Federal University of Juiz de Fora.

Regional Regulations for Biotherapeutics 
Thursday, September 11, 2014
9:15 - 10:25
Gávea B
Lino Barañao
Minister for Science, Technology & Innovative Production of Argentina

Minister of Science, Technology and Productive Innovation of Argentina since 2007. Chairman of the National Agency for Scientific and Technological Promotion 2003-2007. Principal Researcher of CONICET. Institute of Experimental Biology and Medicine and Director of the Laboratory of Reproductive Biology and Animal Biotechnology since 2000.

PhD in Chemical Sciences - Department of Biological Chemistry, School of Exact and Natural Sciences, University of Buenos Aires (UBA). He has published more than 54 papers in international refereed journals, 15 dissemination articles, 5 book chapters and he has also contributed with more than 100 opinion articles published in national newspapers. He also directed six doctoral theses.

He has received, among others, the awards presented to the best graduate the Argentine Chemical Association in 1976, and also the Award of the National Academy of Medicine in 1980 for his work on “Experimental Diabetes: molecular alterations in the central and peripheral regulation of the secretion and action of gonadal hormones”.

Regional Biotech Development: Frameworks for Innovation
Wednesday, September 10, 2014 
9:25 - 10:40
Gávea B
Prof. Andreas Baumann
Bayer Pharma AG
Director and Principal Scientific Expert for Biologics within Global Early Development

Prof. Andreas Baumann is Director and Principal Scientific Expert for Biologics within Global Early Development at Bayer Pharma in Berlin, Germany, where his responsibilities cover the global preclinical pharmacokinetic development of biotechnology derived pharmaceuticals. He has more than 20 years experience in drug development in the pharmaceutical industry including small molecules and for the last 14 years focused on non-clinical development of Biologics. Prior his present obligations he was heading the Research Pharmacokinetic Department at Schering AG, Berlin. In parallel, he is Professor of Pharmacology & Toxicology, lecturing at Universities in Greifswald and Berlin (Germany). He is member of the BioSafe Leadership Committee of the Biotechnology Industry Organization (BIO).

He has published more than 45 peer-reviewed scientific articles, scientific text book articles and is co-editor of Pharmacokinetic Challenges in Drug Discovery (Springer, 2002).

Regional Regulations for Biotherapeutics 
Thursday, September 11, 2014
9:15 - 10:25
Gávea B
Gabriel Di Blasi
Di Blasi, Parente & Associados
Partner

Gabriel Di Blasi is an industrial engineer, an industrial property agent and an attorney-at-law. His practice covers domestic and international intellectual property law, including: patents, designs, trade secrets, protection of plant varieties, technology licensing, trademarks and copyrights.

His experience in Intellectual Property includes cases before the Brazilian Patent and Trademark Office (BPTO) and regulatory issues before the Ministry of Agriculture and National Health Surveillance Agency (ANVISA), as well as litigation involving data exclusivity, patents, designs, trade secrets and copyrights. Further, Mr. Di Blasi provides counseling on technology management and makes appearances before the government agencies responsible for Brazilian bio-diversity, among others.

He is a member of the Biotech Committee (COMBIO) of the São Paulo Industries Federation (FIESP) and a postgraduate Professor at Universidade do Rio de Janeiro (UERJ) in Intellectual Property Law. Mr. Di Blasi has also been officially designated as a Patent Technical Expert for the Brazilian Courts.

The Innovation Ecosystem in Brazil: From Biofuels to Biotherapeutics
Wednesday, September 10, 2014 
10:45 - 11:45
Vidigal A+B+C
Cesar Augusto Bonine
Fibria S.A.
Regulatory Affairs Manager

Cesar Bonine is a Forestry Engineer, Master Science in Genetics at UNESP and MBA in Knowledge, Technology and Innovation at FIA/USP. He has more than 20 years of experience in forestry, having worked for companies such as Lwarcel Celulose, Votorantim Celulose e Papel and Fibria Celulose. He was responsible for about 10 years of tree breeding and genetic improvement of eucalyptus at Votorantim Celulose e Papel program and actively participated in the development of dozens of varieties of eucalyptus (breeder-inventor in about 15 cultivars). Is currently responsible for Regulatory Affairs, Intellectual Properties and Competitive Intelligence at Fibria Celulose.
 

The Innovation Ecosystem in Brazil: From Biofuels to Biotherapeutics
Wednesday, September 10, 2014 
10:45 - 11:45
Vidigal A+B+C
Andrew Callaway
Deutsche Bank
Managing Director, Global Head of Life Science

Andrew is a Managing Director and Co-Head of Life Sciences for the Americas in Deutsche Bank's Healthcare Investment Banking Group. He joined Deutsche Bank in 2005, focusing on companies in pharmaceuticals, specialty pharmaceuticals and biotechnology. In addition to working with US-based life sciences companies, Andrew has been extremely active in executing transactions in Latin America.

Andrew's recent transaction experience has included advising Cephalon on its sale to Teva Pharmaceuticals; Takeda on its acquisition of Nycomed; Laboratorios Dermatologicos Darier on its sale to GlaxoSmithKline; Neurocrine Biosciences on its recent follow-on offering; and United Therapeutics on its convertible notes offering and concurrent share repurchase.

From 1999 to 2005, Andrew worked in Credit Suisse’s Healthcare Investment Banking Group. Before this, he spent two years at the National Cancer Institute in the Laboratory of Experimental Carcinogenesis as a Cancer Research Training Award Fellow, studying the effects of the heterocyclic amine, PhIP, on gene expression, using differential display and northern blotting. He is also a board member at the American Skin Association.

Incentivizing Entrepreneurship and Investment in Latin America
Wednesday, September 10, 2014
10:45 - 11:45
Copacabana
Dr. Gabriela Gebrin Cezar
​Laboratorios Pfizer LTDA
Senior Director & Head External R&D Innovation Brazil, Latin America & South Africa Worldwide Research and Development

Dr. Gabriela Gebrin Cezar is Senior Director and Head of Pfizer´s ERDI (External Research & Development Innovation) in Brazil and Latin America and South Africa, since April 2012. She was a former scientist in Pfizer´s Global Research and Development division in Groton, CT, USA. In 2005, Dr. Cezar left Pfizer to serve as an Assistant Professor at the University of Wisconsin-Madison (USA), where she led NIH (National Institutes of Health)-funded research programs in stem cell biology and neurodevelopmental disorders. She is also the co-founder and former Chief Scientific Officer of Stemina Biomarker Discovery, a biotechnology company that develops and commercializes stem cell metabolomics assays and biomarkers based on patents and intellectual property she developed at UW-Madison.

From 2008-March 2012, she served as Director and Managing Director, Latin America, of Burrill & Company, a USA-based venture capital and private equity investment management firm, where she led the fund raising and development of a US$150MM life sciences-focused venture capital fund in Brazil, where Pfizer Ventures is one of the investors, along with leading regional institutional (BNDES, FINEP, FUNCEF, Investe Rio, Desenvolve SP, CAF, IADB-Fumin) and strategic private investors (Life Technologies). Dr. Cezar has received many awards and competitive research funding (NIH, National Cancer Institute, National Science Foundation) during her career in the USA, and was appointed by Forbes Magazine as “one of twelve stem cell revolutionaries”. She received a Veterinary Medicine degree from UFMS (Brazil), a MS from Universidade de Brasilia (Brazil), a MS from The University of Edinburgh (Scotland) and a PhD from the University of Wisconsin-Madison (USA).
 

Regional Biotech Development: Frameworks for Innovation
Wednesday, September 10, 2014 
9:25 - 10:40
Gávea B
Mark Crowell
University of Virginia

Mark Crowell was founding Executive Director of UVa Innovation at the University of Virginia and is currently an internationally engaged consultant focusing on best practices in academic innovation and technology transfer.  Previously, Mark served as Vice President for Business Development at the Scripps Research Institute.  He also held similar positions at UNC-Chapel Hill, North Carolina State University and Duke University.  Mark was 2005 President of the Association of University Technology Managers (AUTM), served for five years as Chair of BIO's Technology Transfer Committee, and is a member of numerous regional, national and international boards, committees and organizations.  He recently received the Bayh-Dole Award from AUTM “in recognition of his lifetime contributions to advancing academic innovations.”  In April 2014, the US Chamber of Commerce named UVa Innovation as its 2014 “Champion of Intellectual Property
 

Incentivizing Entrepreneurship and Investment in Latin America
Wednesday, September 10, 2014
10:45 - 11:45
Copacabana
Joseph Damond
BIO
Senior Vice President, International Affairs

As Senior Vice President for International Affairs at the Biotechnology Industry Organization (BIO), Mr. Damond is responsible for developing and implementing the industry association’s program of international advocacy and outreach, including the areas of trade policy and foreign government relations.

Prior to taking his position at BIO, Mr. Damond was Vice President for International Government Relations in Pfizer’s Washington Office from 2006-2011.
Prior to his appointment at Pfizer in 2006, Mr. Damond was with the Pharmaceutical Research and Manufacturers of America (PhRMA) for five years as Deputy Vice President for International Affairs.

Before coming to PhRMA, Mr. Damond spent 12 years as a trade negotiator at the Office of the United States Trade Representative, where his last assignment, from 1999-2001, was as Deputy Assistant U.S. Trade Representative for Asia and Pacific/APEC Affairs. Prior to his time at USTR, Mr. Damond also spent four years at the U.S. Commerce Department, working on bilateral and multilateral trade negotiations.

Mr. Damond received his Master’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs in 1985, and his undergraduate degree magna cum laude from  Georgetown University, School of Foreign Service, in 1983.  
 

Regional Regulations for Biotherapeutics 
Thursday, September 11, 2014
9:15 - 10:25
Gávea B
Maria Sueli Felipe
ABDI - Brazilian Agency for Industrial Development
Innovation Coordinator

Undergraduation in chemistry (1975) and Master in Biological Sciences / Molecular Biology (1978) at the Federal University of Brasilia (UNB), Ph.D. in Biochemistry at São Paulo University (USP) and University of Manchester Institute of Science and Technology (UMIST- UK); former director of Development Programs and Policy’s Department at the Brazilian Ministry of Science Technology and Innovation (MCTI); full professor (1980 to 2010) and senior researcher (currently) at UNB. Coordinated the genome project network of the Brazilian Midwest area; member of the National Network of the Brazilian Genome; former director of the post-graduation program and currently a professor at the Universidade Católica de Brasília (Catholic University of Brasilia - PUC); member of Innovation and Technology Consultant Center (Nati) from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - National Counsel of Technological and Scientific Development); currently answer for the coordination of Innovation at the Agência Brasileira de Desenvolvimento Industrial (ABDI - Brazilian Agency for Industrial Development) on projects with biotechnology and nanotechnology industries.

Global Connections in Innovation and Business: The Brazilian Diaspora as a Facilitator
Wednesday, September 10, 2014 
17:30-18:25
Copacabana
Henrique Krüger Frizzo 
Trench, Rossi E Watanabe
Partner

Henrique Krüger Frizzo is graduated from Universidade de São Paulo with a degree in Law in 2003. LL.M in State and Governmental Affairs at Escola de Formação de Governantes, associated with Universidade de São Paulo in 2004. Extension Course on PUBLIC-PRIVATE PARTNERSHIPS (PPPs) at Escola Superior do Ministério Público de São Paulo - 2005. Specialization in "Contracts with the Public Administration", at Fundação Getulio Vargas -- 2007. Partner of Trench, Rossi & Watanabe Advogados, his area of expertise is Public Law, Government Affairs and Regulatory, with focus on consultancy matters. He is the head of the Pharmaceutical and Life Sciences practice at Trench, Rossi & Watanabe. Mr. Frizzo is recognized by Chambers & Partners, Anuário da Advocacia  and Latin Lawyer as a leading lawyer in Public Law and Life Sciences. He is a speaker in events related to compliance in contracts with the government and regulatory.

Tech Transfer: Industry and University Collaborations
Wednesday, September 10, 2014
16:30 - 16:55
Vidigal A, B, & C
James C. Greenwood
Biotechnology Industry Organization 
President & CEO

James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO), which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the world. He represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, he served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction, led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, he served in the Pennsylvania General Assembly (1981-86) and in the Pennsylvania Senate (1987-1992). He graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. 
 

Welcome Address
Wednesday, September 10, 2014
9:00 - 9:25
Gávea B
Hubert Guarino
Sanofi Pasteuraz
General Manager

Hubert worked in different roles in the pharmaceutical industry both in Pharma and in Biological business divisions. His career so far embraced experiences in Brazil and in the international arena in France and Spain. Hubert held several positions as Business Intelligence Manager, Marketing Director, Commercial Effectiveness Director, Hospital Business Unit Director, General Care BU Director prior to assume the Sanofi Pasteur GM position in Brazil.
Hubert has a Master of Sciences in Management from the Graduate Business School of Marseille – France, he is also alumni from INSEAD (France) and from Harvard Business School (USA).
 

PDPs and the Policy Landscape: Impacts for Patients and the Health Industrial Complex in Brazil
Thursday, September 11, 2014
14:00-14:55
Vidigal A, B, & C
 
Carlos Eduardo Eliziário de Lima
Dannemann Siemsen Advogados
Partner

Carlos Eduardo Eliziário de Lima, a lawyer and industrial property agent, is a partner at the Dannemann Siemsen firm where he has worked since 2005.

Having graduated in Law from the Mackenzie Presbyterian University, and with a post-graduate degree in Business Contracts from the Getulio Vargas Foundation (FGV) Law School in Sao Paulo and a Continued Education Course in Innovation Law from the FGV Law School in Rio, Carlos Eduardo works mainly in the following areas: contracts, focussing on technology supply contracts, licensing of industrial property, service provision contracts, contracts involving the negotiation of copyright, franchising, distribution, agency/commercial representation, joint ventures, confidentiality agreements, agreements between public entities and intellectual property in general.

Tech Transfer: Industry and University Collaborations
Wednesday, September 10, 2014
16:30 - 16:55
Vidigal A, B, & C
Jaderson Lima
Sanofi
Medical and Scientific Alliances Director

Dr. Jaderson Lima is Adjunct Professor, School of Medicine (UFRJ), and the Medical and Scientific Alliances Director of Sanofi Brazil since 2011, after being the Medical Director of the same company from 1998 to 2010. He is a member of Interfarma Innovation Committee; ex-Member of the International Program on Chemical Safety (IPCS-INTOX / WHO) and Drugdex Editorial Board (Micromedex - Thompson Reuters).

The Innovation Ecosystem in Brazil: From Biofuels to Biotherapeutics
Wednesday, September 10, 2014 
10:45 - 11:45
Vidigal A+B+C
Mike Lu
Brazilian Platform for Biofuels and Civilaviation 
Chairman

Mike Lu, biologist, and business administrator, CEO of Curcas Diesel Brasil, a systems integration company engaged in the implementation of an integrated biojetfuel value chain in Brazil. He has organized the biojetfuel test flights of TAM and Gol airlines, and the first biojetfuel commercial flight in Brazil by GOL last October. Founder of ABPPM - Brazilian Jatropha Growers Association, Coordinator of the Steering Committe of the Brazilian Biojetfuel Platform.

The Innovation Ecosystem in Brazil: From Biofuels to Biotherapeutics
Wednesday, September 10, 2014 
10:45 - 11:45
Vidigal A+B+C
Maria Paula Marques
Allergan Latin America
Vice President Regulatory and Scientific Affairs

Paula (Marques), as everybody knows her, has more than 25 years of experience in World-class Manufacturing Techniques, Pharmaceutical technology, Regulatory, Compliance, GMP and Safety standards, with solid experience on Biologics, Pharmaceutical and Medical Devices products.

Paula joined Allergan in March, 1996. During her tenure she has made a significant contribution to Allergan growth in Latin America and supported the change from an eye care business to a global specialty pharmaceutical and medical device company. She acted as a leader in several functions namely; Technology Transfer, Manufacturing, Quality Assurance and Regulatory Affairs.  Before joining Allergan Paula served in the Research and Development area at HMR (former Sanofi Aventis).

Paula holds a Diploma in Pharmaceutical Sciences and a Masters in Business Administration. 

PDPs and the Policy Landscape: Impacts for Patients and the Health Industrial Complex in Brazil
Thursday, September 11, 2014
14:00-14:55
Vidigal A, B, & C
Mauricio Neves
BNDES - Brazilian Development Bank
Superintendent of Industrial Division

Mauricio Neves holds a Ph.D. in Industrial Engineering from COPPE / UFRJ and a MSc. in Public Policies for Science, Technology and Innovation from SPRU – University of Sussex.  He has been working at the Brazilian Development Bank (BNDES) for 15 years, leading several executive positions in the areas of industry and infrastructure. For 5 years he headed the Department of ICTs and is currently the Superintendent of Industrial Division, responsible for the sectors of Biofuels, Consumer Goods, Capital Goods, Retail and Services, Culture, Tourism, Pharmaceutical, ICT, Automotive and Aerospace. In addition to operating lines of credit, it is incumbent to the Industrial Division to participate in the formulation and implementation of public policies for the sectors of its scope, as well as representation on national and foreign boards and councils. He is also an adjunct professor at the State University of Rio de Janeiro.

Incentivizing Entrepreneurship and Investment in Latin America
Wednesday, September 10, 2014
10:45 - 11:45
Copacabana
Eliseu de Oliveira
Georgetown University
NCI-CBC Program Scientific Manager

Dr. Eliseu de Oliveira is the scientific coordinator of Georgetown University Center for Drug Discovery in the Chemical Biology Consortium (CBC) of the National Cancer Institute of the United States. His research is focused on drug design and discovery of new therapeutics to treat cancer, inflammation, pain, and CNS disorders. He is also a lecturer in the masters program of biotechnology of Georgetown. Dr. De Oliveira graduated from the University of São Paulo (PhD in Medicinal Chemistry, Masters in Organic Chemistry), followed by postdoctoral stints in the US. He is the co-founder and active leader of the Brazilian Expert Network – BEN-DC, whose focus is on bridging the innovation gap between Brazil and the US. Dr. de Oliveira was recently awarded the 1st Brazil Diaspora Award for his significant contributions to the project Brazil Diaspora Network of ABDI.
 

Global Connections in Innovation and Business: The Brazilian Diaspora as a Facilitator
Wednesday, September 10, 2014 
17:30-18:25
Copacabana
Luiz Henrique Mourão do Canto Pereira
Biotecsur Platform Commission
Representative of the Brazilian Government

Mr. Canto graduated in Dentistry and obtained his MSc and PhD from the University of Sao Paulo. He worked as a research scientist at the Max Planck Institute for Biological Cybernetics in Tuebingen, Germany (2006-2007) and he was a postdoctoral fellow at the Department of Psychiatric at University of Sao Paulo (2008-2009) before becoming General Coordinator For Biotechnology and Health at MCTI. Mr. Canto is involved in many international collaborations and is member of several national and internacional Councils and Committees.

Regional Biotech Development: Frameworks for Innovation
Wednesday, September 10, 2014 
9:25 - 10:40
Gávea B
Dr. Humberto Pereira
EMBRAER
Vice President of ANPEI and Director 

Humberto Luiz de Rodrigues Pereira, Vice-President, Engineering - Executive Jets, is responsible for the development, certification and support the operation to all
executive aviation products.
Humberto has been working for Embraer for 25 years. He started his carrier as a stress engineer, working in the development of several products such as EMB-120 - Brasilia and EMB-312 – Tucano. He led the ERJ-145 Structural Engineering Team being responsible for the design of the entire primary structure of this airplane.
In 1998, he was assigned Manager of Structural Engineering responsible for all Embraer airplanes, including EMBRAER 170 and EMBRAER190. In 2001, he became a member of the Aviation Rulemaking Advisory Committee.
He was assigned Product Support Engineering Director in 2005, involved in all engineering aspects related to Embraer airplanes in operation. In 2007 he took over as Director of Development Engineering dedicated to all Embraer development products.
Since 2009, he has taken over the position of Director of Engineering for Executive Aviation Market, responsible for all products, including aircrafts in development phase and those which are in operation. Among these aircrafts, there are in operation: Phenom 100, Phenom 300, Lineage 1000, Legacy 600 and Legacy 650 and, finally, at full development is the Legacy 500.
He was graduated from Federal University of Minas Gerais (Universidade Federal de Minas Gerais – UFMG) in Mechanical Aeronautical Engineering and specialized in Aeronautical Structures at Aeronautics Technological Institute (Instituto Tecnológico de Aeronáutica – ITA).
 

The Innovation Ecosystem in Brazil: From Biofuels to Biotherapeutics
Wednesday, September 10, 2014 
10:45 - 11:45
Vidigal A+B+C
Marité Prieto
Amgen
Regulatory Affairs, Safety and Compliance Director 

Marité Prieto Faria is the Regulatory Affairs, Safety and Compliance Director of Amgen since April, 2012. Prior to this position at Amgen, Mrs. Prieto worked at Eli Lilly and Co. as Therapeutic Area Leader (Aug 2002 – Jan 2004), then as Clinical Operations Manager (May 2007 – Apr 2007) and at last as Regulatory Affairs Senior Manager (May 2007 - Mar 2012). Mrs. Prieto has a bachelor degree in Pharmacy (1999) from Pharmacy and Biochemistry Faculty of University of São Paulo. She has a postgraduate degree in Business Management (2004) from the Economics and Business Faculty of University of São Paulo (2004) and she also has a MBA in Business Development (2005) from the same institution. Mrs. Prieto has the Portuguese as her mother language and she is fluent in English and Spanish as well.

Regional Regulations for Biotherapeutics 
Thursday, September 11, 2014
9:15 - 10:25
Gávea B
Eduardo Rodrigues de Rezende
Diaspota Brazil Network
Coordinator

PhD in International Economics Relations by the Academy of Economics Studies of Bucharest, Romania, Eduardo Rezende works currently at the Brazilian Agency of Industrial Development in charge of the Diaspora Brazil Network. Previously, he was the technical coordinator of the Brazil European Union Project to Support the International Insertion of Brazilian Small and Medium Enterprises which was implemented by the same Agency. He also taught Economics in the Cambridge School of Bucharest. 
 

Global Connections in Innovation and Business: The Brazilian Diaspora as a Facilitator
Wednesday, September 10, 2014 
17:30-18:25
Copacabana
Andrew Robertson
Merck, Sharpe & Dohme
Director for US Regulatory Policy

Andrew Robertson works in Global Regulatory Affairs at Merck, Sharpe & Dohme, focusing on regulatory policies concerning vaccines, biologics, in vitro diagnostics, mobile medical apps and software medical devices.  He has over 12 years of experience working in life sciences, policy, and law, including a faculty research position in genetics at the Wellcome Trust Sanger Centre, AAAS S&T Policy Fellowship at the HHS Office of the Secretary, and as the Chief Policy Officer at BIO Ventures for Global Health through a grant from the Bill & Melinda Gates Foundation.  Andrew has authored multiple peer-reviewed articles on topics pertaining to health product development, in vitro diagnostics, health technology and genetics privacy, and innovation incentives.  He holds a JD from the University of California, Berkeley, School of Law, a Ph.D. in molecular biology from Cambridge University (as a Gates Cambridge Scholar), and a MS and BS in genetics from the University of California, San Diego. 

Clinical Trials: Addressing Challenges Through Global Expertise and Best Practices
Thursday, September 11, 2014
10:30 - 11:45
Vidigal A+B+C
 
Maria Eugenia Sanchez
Lilly
Regional Director Clinical Operations Latin America

Graduated as Pharmaceutical Chemical Biologist at Universidad La Salle and holds a Diploma in Finance. Her  professional experience in the Pharmaceutical Field is of 21 years. During this time, she has worked in different areas such as Regulatory affairs, Manufacturing, Marketing and Clinical Research. Her career started in Regulatory affairs as Regulatory associate. Then she had different roles within Eli Lilly like Manufacturing as Export Coordinator for Central America, Dominican Republic and Haiti, marketing as Neuroscience marketing product associate. Since 1997 she has been in the Clinical Research field, starting as Oncology CRA. By 1998, she was the Clinical Operations Manager for Eli Lilly.

In 2010 she got the role of Clinical Operations Director for Latin America. In this role she  was  responsible for Lilly’s  clinical operations related to Ph I-PhIV trials in Latin America and implementation  for Autoimmune, Bone, Urology, Men’s health, Neuroscience, Diabetes, Oncology, Cardiovascular trials in Emerging Markets. Involved in trial allocation, site activation, initiation and execution. Responsible to make sure trials are implemented according to all good practices/standards/local regulations, Policies & Procedures. Awards: Best OUS Green Belt Six Sigma project - by Eli Lilly & Company; Best Pharma Company in Clinical Research (Eli Lilly Mexico, SA de CV) –  by CANIFARMA (Mexican Pharmaceutical Chamber); Lilly Quality Advocate Award – by Eli Lilly & Company

Clinical Trials: Addressing Challenges Through Global Expertise and Best Practices
Thursday, September 11, 2014
10:30 - 11:45
Vidigal A+B+C
Carolina da Silva, Coordinator of the Biotechnology Sector Council - National Craft, Small and Medium Enterprises (DINAPYME) / Ministry of Industry, Energy and Mining, Uruguay 

With a Degree in Political Science and International Relations, a Postgraduate Diploma in International Studies and Master's in Organizational Studies in progress, Carolina da Silva is currently the Director of Productive Articulation at the Ministry of Industry, Energy and Mining of Uruguay and Coordinator of National Sectorial Council of Biotechnology. This Council is a public-private collaboration space where representatives from government, business leaders, academia, trade unions and workers participate to design and implement industry-level growth strategies in biotechnology.
Her area of expertise is the design, implementation, monitoring and evaluation of policy instruments for innovation and development. In the last five years, she focused on the design, evaluation and management of public - private initiatives for innovative and productive development. She has worked at consultancy level and advice in private companies as well as various international organizations (EU, IDB, UNICEF, UNDP and UNIDO)

Regional Biotech Development: Frameworks for Innovation
Wednesday, September 10, 2014 
9:25 - 10:40
Gávea B
Eduardo Emrich Soares
Biominas Brasil
Chief Executive Officer & President

Eduardo Emrich Soares is the President & CEO of Biominas Brasil since August 2003. He has been a member of the Board of Directors of several life sciences companies, such as Prodimol, Biocancer and Alvos, and has also been the industry representative on several initiatives aimed at developing the life sciences sector in Brazil. He has over 15 years of experience in business structuring and administration, project & business management, development and technical analysis in the industry. Eduardo works in the articulation of leading national and international companies from various areas of the life sciences sector, research centers, clusters and incubators in several countries.

Eduardo has a degree in Biology, with emphasis in Biochemistry and Molecular Biology, from the Federal University of Minas Gerais - UFMG (Belo Horizonte, MG), a postgraduate degree in Financial Management from Fundação Dom Cabral - FDC (Belo Horizonte, MG) and in Business Management from Fundação Getúlio Vargas - FGV (Belo Horizonte, MG). 

Welcome Address
Wednesday, September 10, 2014
9:00 - 9:25
Gávea B
Ricardo Tolentino
Instituto Butantan
Head of the New Business

Ricardo Tolentino has been a Project Manager and New Business development at Instituto Butantan. Before he had worked as consultant at K2 Achievements in Brazil, Angola and South Africa, specializing in strategic planning and business analysis. Tolentino alternated work as a consultant with the performance of executive functions. Was project manager at the Faculty of Medicine in the University of São Paulo and operational manager of the Hospital Dr. Christovão da Gama, Santo André, Brazil. Ricardo has a degree from the Universidade de Campinas (UNICAMP), with a specialization course in Hospital Administration and Health Systems at Escola de Administração de Empresas de São Paulo da Fundação Getulio Vargas (FGV-EAESP) and post graduate studies at Universidade de São Paulo (USP).

PDPs and the Policy Landscape: Impacts for Patients and the Health Industrial Complex in Brazil
Thursday, September 11, 2014
14:00-14:55
Vidigal A, B, & C
Alan Vanderborght
Torreya Emerging Markets
CEO

Alan Vanderborght is the founder and CEO of Torreya Emerging Markets, a boutique advisory firm focused on mergers and acquisitions, licensing, and commercialization of pharmaceutical products and medical devices in emerging markets. Prior to founding Torreya Emerging Markets, Alan worked at Bristol-Myers Squibb in various position including Head of Commercial Operations and Business Development for 17 countries in Latin America. Alan has a Bachelor’s degree in Business and International Affairs form ICHEC in Brussels, Belgium, an MBA in marketing from George Mason University in Fairfax, Virginia, and a Marketing Executive Certificate from the Wharton School of Business in Philadelphia, Pennsylvania. Alan is also currently completing a Master in Biotechnology at the University of Maryland. Alan is past president of the New-Hope Lambertville Rotary Club and a board member of Balinbac Therapeutics.

Incentivizing Entrepreneurship and Investment in Latin America
Wednesday, September 10, 2014
10:45 - 11:45
Copacabana
Antonio Werneck
Instituto Vital Brazil 
President

Physician graduated from the School of Medicine and Surgery of Rio de Janeiro, with a Specialization in Health Planning. Has a Master Degree in Public Health by the National School of Public Health (Oswaldo Cruz Foundation). His dissertation was ‘The models of governance and sustainability of Brazilian public laboratories: case of Farmanguinhos and Vital Brazil’, and actually is President of the Institute Vital Brazil since September 2007, a benchmark scientific center founded in 1919 by Vital Brazil Mineiro da Campanha, a most of importants Brazilian  Scientists.

Antonio Werneck started his professional life as a physician in poor communities and in clinics of rural workers Unions. At that time, the focus was to expanding the family health care model. Over the ensuing years Werneck worked in the planning and management in all three levels of the Brazilian Public Health System: Municipal, State and Federal and has held several positions as the head of a primary care unit earlier in his career, all the way to National Secretary of Health Attention in the Brazilian Health Ministry, having occupied, as well, the position of vice-secretary of health in the city of Rio de Janeiro.
Since 2004, his work is focused in the field of Science, Technology and Innovation with special interest in the ‘Life Sciences’.

Presently, two main subjects are taking his interest: the establishing of a common scientific reference network for training, research and production aimed at setting long-term research agenda in the Life Sciences biotech field; and the creation, developing and improving, in the State of Rio de Janeiro, of a technology platform based on public-private partnerships as a means to ensure  the building of a biotechnology cluster in Rio de Janeiro.

Incentivizing Entrepreneurship and Investment in Latin America
Wednesday, September 10, 2014
10:45 - 11:45
Copacabana